These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21663508)

  • 1. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy.
    Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F
    Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive transformation of germinal centers and Hodgkin lymphoma: more insights but maybe more confusion?
    Sweetenham JW; Polliack A
    Leuk Lymphoma; 2011 Nov; 52(11):2041-2. PubMed ID: 21888616
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.
    Rehwald U; Schulz H; Reiser M; Sieber M; Staak JO; Morschhauser F; Driessen C; Rudiger T; Muller-Hermelink K; Diehl V; Engert A;
    Blood; 2003 Jan; 101(2):420-4. PubMed ID: 12509381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
    Coiffier B; Radford J; Bosly A; Martinelli G; Verhoef G; Barca G; Davies A; Decaudin D; Gallop-Evans E; Padmanabhan-Iyer S; Van Eygen K; Wu KL; Gupta IV; Lin TS; Goldstein N; Jewell RC; Winter P; Lisby S;
    Br J Haematol; 2013 Nov; 163(3):334-42. PubMed ID: 24032456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
    Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
    Ekstrand BC; Lucas JB; Horwitz SM; Fan Z; Breslin S; Hoppe RT; Natkunam Y; Bartlett NL; Horning SJ
    Blood; 2003 Jun; 101(11):4285-9. PubMed ID: 12586628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
    Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
    J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma.
    Hartmann S; Winkelmann R; Metcalf RA; Treetipsatit J; Warnke RA; Natkunam Y; Hansmann ML
    Hum Pathol; 2015 Nov; 46(11):1655-61. PubMed ID: 26410017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
    Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
    Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation.
    Laurenti L; De Padua L; Battendieri R; Tarnani M; Sica S; Blasi MA; Savino G; Leone G
    Leuk Res; 2011 May; 35(5):682-4. PubMed ID: 21334067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
    Advani RH; Hoppe RT
    Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
    Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
    Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma.
    Linck D; Lentini G; Tiemann M; Fauser AA; Parwaresch R; Basara N
    Leuk Lymphoma; 2005 Feb; 46(2):285-8. PubMed ID: 15621815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.